Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Rita Assi, Hagop M. Kantarjian, Naval G. Daver, Guillermo Garcia-Manero, Christopher B. Benton, Philip A. Thompson, Gautam Borthakur, Tapan M. Kadia, Yesid Alvarado, Elias J. Jabbour, Marina Y. Konopleva, Koichi Takahashi, Steven M. Kornblau, Courtney D. DiNardo, Zeev E. Estrov, Wilmer Flores, Sreyashi Basu, James P Allison, Padmanee Sharma, Sherry A. Pierce, Allison Pike, Jorge E. Cortes, Farhad Ravandi
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2902482179